Dexcom Inc DXCM
We take great care to ensure that the data presented and summarized in this overview for DEXCOM INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DXCM
View all-
Vanguard Group Inc Valley Forge, PA47.4MShares$3.57 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY34.5MShares$2.6 Billion0.09% of portfolio
-
Capital Research Global Investors Los Angeles, CA17.9MShares$1.35 Billion0.26% of portfolio
-
State Street Corp Boston, MA16.7MShares$1.25 Billion0.05% of portfolio
-
Baillie Gifford & CO15MShares$1.13 Billion0.77% of portfolio
-
Sands Capital Management, LLC Arlington, VA10.3MShares$776 Million2.2% of portfolio
-
Geode Capital Management, LLC Boston, MA9.94MShares$748 Million0.05% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL8.09MShares$608 Million0.16% of portfolio
-
Capital World Investors Los Angeles, CA7.63MShares$574 Million0.08% of portfolio
-
Jennison Associates LLC6.93MShares$522 Million0.29% of portfolio
Latest Institutional Activity in DXCM
Top Purchases
Top Sells
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Transactions at DXCM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
3,500
-4.15%
|
$262,500
$75.51 P/Share
|
|
Sep 16
2024
|
Bridgette P Heller Director |
SELL
Open market or private sale
|
Direct |
1,000
-3.94%
|
$70,000
$70.0 P/Share
|
|
Sep 09
2024
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
746
-0.28%
|
$51,474
$69.15 P/Share
|
|
Sep 09
2024
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
746
-0.88%
|
$51,474
$69.15 P/Share
|
|
Sep 09
2024
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
426
-0.56%
|
$29,394
$69.15 P/Share
|
|
Aug 30
2024
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
686
-1.03%
|
$48,020
$70.0 P/Share
|
|
Jul 31
2024
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
652
-0.97%
|
$44,988
$69.55 P/Share
|
|
Jun 28
2024
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
659
-0.98%
|
$75,126
$114.29 P/Share
|
|
Jun 18
2024
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
3,306
-2.78%
|
$386,802
$117.0 P/Share
|
|
Jun 17
2024
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
2,694
-1.45%
|
$312,504
$116.7 P/Share
|
|
Jun 14
2024
|
Bridgette P Heller Director |
SELL
Open market or private sale
|
Direct |
1,000
-3.8%
|
$113,000
$113.55 P/Share
|
|
Jun 10
2024
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
745
-0.87%
|
$85,675
$115.05 P/Share
|
|
Jun 10
2024
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
745
-0.28%
|
$85,675
$115.05 P/Share
|
|
Jun 10
2024
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
427
-0.56%
|
$49,105
$115.05 P/Share
|
|
May 31
2024
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
652
-0.96%
|
$77,588
$119.24 P/Share
|
|
May 22
2024
|
Richard Alexander Collins Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,632
+50.0%
|
-
|
|
May 22
2024
|
Karen M Dahut Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,613
+50.0%
|
-
|
|
May 22
2024
|
Rimma Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,632
+28.39%
|
-
|
|
May 22
2024
|
Mark G Foletta Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,973
+50.0%
|
-
|
|
May 22
2024
|
Bridgette P Heller Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,618
+9.04%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 316K shares |
|---|---|
| Bona fide gift | 20.9K shares |
| Open market or private sale | 298K shares |
|---|---|
| Sale (or disposition) back to the issuer | 12.4K shares |
| Bona fide gift | 28.6K shares |